

65th American Society of Hematology Annual Meeting and Exposition
December 9-12, 2023
San Diego, California
Abstracts¹

CCTG SC.26: Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia

Time: Saturday, December 9, 2023: 5:30-7:30 PM
Location: Halls G-H (San Diego Convention Centre)
Type: Poster
Session: 613 – Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I
Presenter: Troy Climans
Abstract: *Canadian Cancer Trials Group SC.26 - Emotion and Symptom-Focused Engagement (EASE): A Multi-Site Randomized Controlled Trial of an Intervention for Individuals with Acute Leukemia (#1494)*
Authors: Climans T, Zimmermann C, Hay AE, Richardson H, Villeneuve P, Mozessohn L, Schuh AC, Dyba J, Hannon B, Lee D, Buckstein R, Malakian A, Fitzgibbon K, Lefebvre J, Tu W, Rodin G
Link: <https://ash.confex.com/ash/2023/webprogram/Paper174378.html>
Citation:

CCTG HDC.1 / SWOG S1826: A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)

Time: Saturday, December 9, 2023: 2:00 PM
Location: Grand Hall B (Manchester Grand Hyatt San Diego)
Type: Oral
Session: 624 – Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Topics in T Cell, Szary and Hodgkin Lymphoma
Presenter: Sarah Rutherford
Abstract: *Nivolumab-AVD Is Better Tolerated and Improves Progression-Free Survival Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma Enrolled on SWOG S1826 (#181)*
Authors: Rutherford CS, Li H, Herrera AF, Leblanc M, Ahmed S, Davison KL, Casulo C, Bartlett NL, Tuscano JM, Hess B, Torka P, Kumar P, Jacobs RW, Song JY, Castellino SM, Kahl BS, Leonard JP, Smith SM, Friedberg JW, Evens AM
Link: <https://ash.confex.com/ash/2023/webprogram/Paper180114.html>
Citation:

¹ A searchable directory of abstracts is available using this link ... <https://ash.confex.com/ash/2023/webprogram/start.html>.

CCTG HDC.1 / SWOG S1826: A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)

Time: Sunday, December 10, 2023: 5:15 PM
Location: Grand Hall B (Manchester Grand Hyatt San Diego)
Type: Oral
Session: 624 – Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Advances in the Treatment of Hodgkin Lymphoma
Presenter: Kara Kelly
Abstract: *Progression-Free Survival (PFS) and Toxicity with Nivolumab-AVD Compared to Brentuximab Vedotin-AVD in Pediatric Advanced Stage (AS) Classic Hodgkin Lymphoma (cHL), Results of SWOG S1826 (#610)*
Authors: Castellino SM, Li H, Herrera AF, Punnett A, Leblanc M, Parsons SK, Hodgson D, Keller F, Drachtman RA, Lambie A, Forlenza CJ, Doan A, Rutherford SC, Evens AM, Little RF, Smith MA, Song JY, Smith SM, Friedberg JW, Kelly KM
Link: <https://ash.confex.com/ash/2023/webprogram/Paper180107.html>
Citation:

CCTG HD.6: A Phase III Study of Radiotherapy or ABVD Plus Radiotherapy versus ABVD Alone in the Treatment of Early-Stage Hodgkin's Disease

Time: Sunday, December 10, 2023: 6:00-8:00 PM
Location: Halls G-H (San Diego Convention Centre)
Type: Poster
Session: 624 – Hodgkin Lymphomas and T/NK Cell Lymphomas: Clinical and Epidemiological: Poster II
Presenter: Andrew Evens
Abstract: *Development and Validation of the Early-Stage Hodgkin Lymphoma (HL) International Prognostication Index (E-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium (#3058)*
Authors: Evens AM, Rodday AM, Maurer MJ, Advani RH, Andre M, Gallamini A, Hay AE, Hodgson D, Hoppe RT, Hutchings M, Johnson P, Link BK, Opat S, Raemaekers JM, Upshaw J, Xiang Q, Counsell N, Parsons SK, Radford J
Link: <https://ash.confex.com/ash/2023/webprogram/Paper173320.html>
Citation:

CCTG ALC.3 / SWOG S1203: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)

Time: Sunday, December 10, 2023: 6:00-8:00 PM
Location: Halls G-H (San Diego Convention Centre)
Type: Poster
Session: 613 – Acute Myeloid Leukemias: Clinical and Epidemiological: Poster II
Presenter: Michelle Zhang
Abstract: *Class III Obesity Is Associated with Worse Overall Survival in Previously Untreated Younger Patients with Acute Myeloid Leukemia Enrolled on SWOG 1203 (#2863)*
Authors: Zhang MY, Othus M, McMillen KK, Erba HP, Garcia-Manero G, Pagel J, Sorrow M, Percival MEM
Link: <https://ash.confex.com/ash/2023/webprogram/Paper189455.html>
Citation:

CCTG ALC.4 / ECOG E1910: A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults

Time: Sunday, December 10, 2023: 6:00-8:00 PM
Location: Halls G-H (San Diego Convention Centre)
Type: Poster
Session: 614 – Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Presenter: Selina Luger
Abstract: ***Assessment of Outcomes of Consolidation Therapy By Number of Cycles of Blinatumomab Received in Newly Diagnosed Measurable Residual Disease Negative Patients with B-Lineage Acute Lymphoblastic Leukemia: In the ECOG-ACRIN E1910 Randomized Phase III National Clinical Trials Network Trial (#2877)***
Authors: Luger SM, Sun Z, Mattison RJ, Paietta E, Roberts KG, Zhang Y, Racevckis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Liedtke M, Bergeron J, Wood BL, Zhao Y, Wu G, Chang TC, Zhang W, Pratz KW, Dinner SN, Frey NV, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, DeAngelo DJ, Sharon E, Little RF, Erba HP, Stone RM, Mullighan CG, Litzow MR, Tallman MS
Link: <https://ash.confex.com/ash/2023/webprogram/Paper189648.html>
Citation:
